EUVIMEDEUVIMED entdecken
Kohortenstudie

Clinical outcomes after switching from mepolizumab to benralizumab in eosinophilic granulomatosis with polyangiitis: A single-centre retrospective cohort study

Daichi Umemoto iD, Eri Iwai-Kanai, Kazuhiro Hatta, Hirofumi Miyake iD

Modern Rheumatology · 04.08.2026

DOI: 10.1093/mr/roag062 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Modern Rheumatology, online erschienen am 04.08.2026. Verfasst von Daichi Umemoto und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Internal Medicine, Tenri Hospital, Tenri, Nara, Japan. Die Arbeit nennt 16 Literaturangaben. Gefördert von: JSPS, Ministry of Education, Culture, Sports, Science, and Technology, Japan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To investigate the impact of switching to benralizumab on flare risk in patients with eosinophilic granulomatosis with polyangiitis (EGPA) previously treated with mepolizumab.

Methods

We conducted a single-centre retrospective cohort study including 26 patients with EGPA who received mepolizumab. A landmark analysis was performed at 910 days after mepolizumab initiation (median time to switching), and patients were grouped according to treatment. The primary outcome was disease flares requiring treatment intensification. We used a Cox model with treatment switching as a time-dependent covariate.

Results

In the landmark analysis, the benralizumab group (n = 4) had a higher flare rate than the mepolizumab group (n = 10) (log-rank test, P = .002). However, the Cox model did not converge, and the time-dependent analysis yielded an imprecise estimate (hazard ratio 3.14, 95% confidence interval 0.31–32.02). The 1-year flare-free rate after switching to benralizumab (n = 19) was 94.1%, and no severe flares occurred. Most patients had low disease activity at switching, and switching was primarily driven by patient preference.

Conclusions

Short-term flare-free survival after switching to benralizumab was high, despite a small number of minor flares. Further evidence is warranted to assess long-term outcomes.

Schlagwörter

Stichwörter der Autor:innen

benralizumabbiologic switchingeosinophilic granulomatosis with polyangiitisflaremepolizumabreal-world datarelapsevasculitis

Autor:innen und Institutionen

  • Department of General Internal Medicine, Tenri Hospital, Tenri, Nara, Japan.
  • Faculty of Health Care, Tenri University, Tenri, Nara, Japan.

ORCID-Profile: Daichi Umemoto, Hirofumi Miyake

Förderung

  • JSPS
  • Ministry of Education, Culture, Sports, Science, and Technology, Japan

Zitieren

APA

Umemoto, D., Iwai-Kanai, E., Hatta, K., & Miyake, H. (2026). Clinical outcomes after switching from mepolizumab to benralizumab in eosinophilic granulomatosis with polyangiitis: A single-centre retrospective cohort study. Modern Rheumatology. https://doi.org/10.1093/mr/roag062

Vancouver

Umemoto D, Iwai-Kanai E, Hatta K, Miyake H. Clinical outcomes after switching from mepolizumab to benralizumab in eosinophilic granulomatosis with polyangiitis: A single-centre retrospective cohort study. Modern Rheumatology. 2026. doi:10.1093/mr/roag062

BibTeX
@article{Umemoto2026,
  author = {Umemoto, Daichi and Iwai-Kanai, Eri and Hatta, Kazuhiro and Miyake, Hirofumi},
  title = {Clinical outcomes after switching from mepolizumab to benralizumab in eosinophilic granulomatosis with polyangiitis: A single-centre retrospective cohort study},
  journal = {Modern Rheumatology},
  year = {2026},
  doi = {10.1093/mr/roag062}
}
Kostenlos starten →